Stock BRM BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bristol-Myers Squibb Company Deutsche Boerse AG

Equities

BRM

US1101221083

Market Closed - Deutsche Boerse AG
Other stock markets
 08:07:29 2024-06-26 EDT 		5-day change 1st Jan Change
39.66 EUR +0.52% Intraday chart for Bristol-Myers Squibb Company +4.41% -14.90%
06-26 2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
06-26 Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • The company has a low valuation given the cash flows generated by its activity.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company is in debt and has limited leeway for investment
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-14.90% 85.52B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 654B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 337B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.44% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 229B
A+
NOVARTIS AG Stock Novartis AG
+13.03% 219B
B-
AMGEN INC. Stock Amgen Inc.
+8.61% 171B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BRM Stock
  5. Ratings Bristol-Myers Squibb Company